Primary driving factors for the growth of hormonal contraceptives market are increasing focus on family planning among the people and continuous support from the government. Furthermore, advancements in hormonal contraception such as the advent of hormonal patches, implants and other innovative drug-device combination products are fuelling the market growth. Moreover, the need for preventing unintended pregnancy, urbanization coupled with user awareness is projected to boost the market growth over the forecast period. According to the World Health Organization (WHO), about 74 million women in low and middle-income countries have unintended pregnancies annually, leading to 25 million unsafe abortions and 47000 maternal deaths.
In addition, companies efforts in producing the innovative hormonal contraceptives with fewer side effects and enhanced efficiency anticipated boosting the usage of hormonal contraceptives in the near future. However, side effects associated with the usage of hormonal contraceptives and availability hormone-free contraceptives may hamper the market growth.
Key Market Trends
Contraceptive Pills Expected to Have Significant Share
In the product segment, contraceptive hormonal pills are expected to have significant share owing to ease of use and availability. Moreover, the availability of pipeline products and their expected commercialization anticipated to boost the segment growth furthermore. Combination hormonal contraceptives are anticipated to have a notable market share due to their better efficiency and success rate in preventing pregnancy. In addition, companies focus on new product launches and advancing the combination hormonal contraceptives may bolster the segment growth. Intrauterine devices anticipated to have notable growth rate due to adaptation of long-acting contraception devices couple with efficiency.
Moreover, the increasing research and development investments and product pipelines in hormonal contraception and new product launch expected to boost the overall market growth.
North America Expected to have Significant Market Share
Owing to the high adoption of hormonal contraceptives, well-established healthcare infrastructure and presence of key market players in the region, North America hormonal contraceptives market is expected to grow at significant rates. According to the Center for Disease Control and Prevention (CDC), in 2015-2017, 72.2 million US woman aged between 19-49 were using contraceptives. In addition, government initiatives in increasing awareness regarding birth control and growing affordability fueling the market growth.
The developed countries in Europe such as United Kingdom and Germany are having well-established healthcare infrastructure and high awareness regarding hormonal contraception which is expected to boost regional growth. The Asia-Pacific region is projected to have considerable growth rate owing to developing healthcare infrastructure and availability of a large pool of population using contraception.
Global hormonal contraceptives market is moderately fragmented and competitive. Market players are focusing on product innovations, new product launches and regional expansions to increase their market share. The key market players operating in clot management devices market include Allergan plc, Afaxys, Inc., Merck & Co., Inc., Pfizer, and Mylan N.V. among others.
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
1.2 Study Assumptions
1.3 Scope of the Study
4.2 Market Drivers
4.2.1 Increasing Focus on Family Planning and Favorable Regulations by Government
4.2.2 Advancements in Hormonal Contraception
4.3 Market Restraints
4.3.1 Availability of Alternative Contraceptive Methods
4.3.2 Health Risks Associated With Hormonal Contraception
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.1 Oral Contraceptives
5.1.2 Skin Patches
5.1.3 Intrauterine Devices
5.1.4 Hormonal Implants
5.2 By Hormone
5.2.1 Progestin Only
5.2.2 Combined Hormone Contraceptives
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.4.1 North America
22.214.171.124 United States
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle-East and Africa
5.4.5 South America
126.96.36.199 Rest of South America
6.1.1 Allergan plc
6.1.2 Afaxys, Inc.
6.1.3 Merck & Co., Inc.
6.1.4 Pfizer Inc.
6.1.5 Mylan N.v.
6.1.6 Bayer AG
6.1.7 Agile Therapeutics
6.1.8 Novartis AG
6.1.9 Johnson & Johnson
6.1.10 The Piramal Group
A selection of companies mentioned in this report includes:
- Allergan plc
- Afaxys, Inc.
- Merck & Co., Inc.
- Pfizer Inc.
- Mylan N.v.
- Bayer AG
- Agile Therapeutics
- Novartis AG
- Johnson & Johnson
- The Piramal Group